Contribution of the BRAF oncogene in the pre‑operative phase of thyroid carcinoma

Rodrigues,Homero  Gustavo Correia; De Pontes,Alana  Abrantes Nogueira; Adan,Luis   Fernando

doi:10.3892/ol.2013.1359

Contribution of the BRAF oncogene in the pre‑operative phase of thyroid carcinoma

Authors:
- Homero Gustavo Correia Rodrigues
- Alana Abrantes Nogueira De Pontes
- Luis Fernando Adan
View Affiliations

Affiliations: School of Medicine, Federal University of Campina Grande, Campina Grande 58.429-140, Brazil, School of Medicine, Federal University of Bahia, Salvador, Bahia 40025-101, Brazil
Published online on: May 22, 2013 https://doi.org/10.3892/ol.2013.1359
Pages: 191-196

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Numerous experiments have been conducted over the last few years aiming to identify molecular markers that show the diagnostic accuracy of fine‑needle aspiration (FNA), particularly in thyroid lesions that are considered indeterminate. Using certain search arguments and previously defined criteria, 37 studies reporting experiments with the BRAF mutation in pre‑operative FNA of the thyroid were selected from the electronic databases PUBMED, MEDLINE, SCOPUS and LILACS, in order to gather evidence with regard to the possible contribution of BRAF in the management of thyroid carcinoma. There were no cases positive for BRAF in follicular carcinomas (FTCs), Hürthle cell carcinomas (HCCs) or medullary thyroid carcinomas (MTCs). Among the 11 cases of anaplastic thyroid carcinomas (ATC), three showed positive results for the BRAF mutation. The number of cases positive for BRAF among the benign lesions was not significant. The average prevalence of BRAF‑positive cases in papillary carcinomas (PTC) was 58.6%, while in follicular variants of papillary carcinoma (FVPTC), the average prevalence was 29.6%. For lesions diagnosed as indeterminate or suspicious, the average prevalence of BRAF positivity in PTC was 48.5%. The experiments included in the present study indicated a specificity of almost 100% and a high predominance of the BRAF mutation in PTC, distinguishing the marker in the planning and medical management of papillary carcinoma of the thyroid.

View Figures

View References

1.	Pilli T, Prasad KV, Jayarama S, Pacini F and Prabhakar BS: Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid. 19:1333–1342. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Alves MLD, Maciel RMB, Valeri FV, Silva MRDD, Contrera JD, Andrade JM, Llorach-Velludo MA and Iazigi N: Prediction of malignancy in the solitary thyroid nodule by physical examination, thyroid scintigraphy, thyroid ultrasound, fine-needle biopsy and serum thyroglobulin: a prospective study of 110 operated patients. Arq Bras Endocrinol Metabol. 46:648–653. 2002.(In Portuguese).
3.	Cerutti JM: Nodule diagnosed as follicullar patterned lesion: are biomarkers the promise? Arq Bras Endocrinol Metabol. 51:832–842. 2007.PubMed/NCBI
4.	Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, Rossi R, Cavazzini L, Roti E and degli Uberti EC: BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol. 161:467–473. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Suster S: Thyroid tumors with a follicular growth pattern: problems in differential diagnosis. Arch Pathol Lab Med. 130:984–988. 2006.PubMed/NCBI
6.	Segura MEA and Magalhães AV: Galectin-3 immunostaining in thyroid neoplasms. J Bras Patol Med Lab. 41:341–346. 2005. View Article : Google Scholar
7.	Rosa MP: Expression of galectin-3 and cytokeratin 19 in the epithelial neoplasm of the thyroid gland and histopathological correlation. Jornal brasileiro de patologia e medicina laboratorial. 41:61–70. 2005.
8.	Cantara S, Capezzone M, Marchisotta S, Capuano S, Busonero G, Toti P, Di Santo A, Caruso G, Carli AF, Brilli L, Montanaro A and Pacini F: Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 95:1365–1369. 2010. View Article : Google Scholar : PubMed/NCBI
9.	Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
10.	Li Y, Nakamura M and Kakudo K: Targeting of the BRAF gene in papillary thyroid carcinoma (review). Oncol Rep. 22:671–681. 2009.PubMed/NCBI
11.	Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M and Tufano R: BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for pre-operative risk stratification in papillary thyroid cancer. J Clin Oncol. 27:2977–2982. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Hwang J, Shin JH, Han BK, Ko EY, Kang SS, Kim JW and Chung JH: Papillary thyroid carcinoma with BRAFV600E mutation: sonographic prediction. Am J Roentgenol. 194:W425–W430. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Hayashida N, Namba H, Kumagai A, Hayashi T, Ohtsuru A, Ito M, Saenko VA, Maeda S, Kanematsu T and Yamashita S: A rapid and simple detection method for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid. 14:910–915. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Yip L, Nikiforova MN, Carty SE, Yim JH, Stang MT, Tublin MJ, Lebeau SO, Hodak SP, Ogilvie JB and Nikiforov YE: Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. 146:1215–1223. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K and Nikiforova MN: Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 94:2092–2098. 2009. View Article : Google Scholar : PubMed/NCBI
16.	Rowe LR, Bentz BG and Bentz JS: Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal. 3:102006. View Article : Google Scholar : PubMed/NCBI
17.	Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F and Santoro M: Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 89:5175–5180. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Sapio MR, Guerra A, Posca D, Limone PP, Deandrea M, Motta M, Troncone G, Caleo A, Vallefuoco P, Rossi G, Fenzi G and Vitale M: Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer. 14:1089–1097. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Xing M: Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol. 321:86–93. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Lee JH, Lee ES and Kim YS: Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 110:38–46. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ and Choi JR: Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology. 253:854–860. 2009. View Article : Google Scholar : PubMed/NCBI
22.	Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, Sidransky D and Westra WH: Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: A potential application for the pre-operative assessment of thyroid nodules. Clin Cancer Res. 10:2761–2765. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Xing MZ, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, Byrne PJ, Wang J, Sidransky D and Ladenson PW: Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab. 89:2867–2872. 2004. View Article : Google Scholar : PubMed/NCBI
24.	Domingues R, Mendonça E, Sobrinho L and Bugalho MJ: Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a pre-operative diagnosis of papillary thyroid carcinoma. Cytopathology. 16:27–31. 2005. View Article : Google Scholar : PubMed/NCBI
25.	Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park do J, Lee HS, Cho BY, Lee ES and Kim SW: Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAFV600E mutation-prevalent area. Clinical Endocrinol (Oxf). 65:660–666. 2006. View Article : Google Scholar : PubMed/NCBI
26.	Jin L, Sebo TJ, Nakamura N, Qian X, Oliveira A, Majerus JA, Johnson MR and Lloyd RV: BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol. 15:136–143. 2006. View Article : Google Scholar : PubMed/NCBI
27.	Pizzolanti G, Russo L, Richiusa P, Bronte V, Nuara RB, Rodolico V, Amato MC, Smeraldi L, Sisto PS, Nucera M, Bommarito A, Citarrella R, Lo Coco R, Cabibi D, Lo Coco A, Frasca F, Gulotta G, Latteri MA, Modica G, Galluzzo A and Giordano C: Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid. 17:1109–1115. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Sapio MR, Posca D, Raggioli A, Guerra A, Marotta V, Deandrea M, Motta M, Limone PP, Troncone G, Caleo A, Rossi G, Fenzi G and Vitale M: Detection of RET/PTC, TRK and BRAF mutations in pre-operative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol. 66:678–683. 2007. View Article : Google Scholar : PubMed/NCBI
29.	Kim SK, Kim DL, Han HS, Kim WS, Kim SJ, Moon WJ, Oh SY and Hwang TS: Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol. 17:118–125. 2008. View Article : Google Scholar : PubMed/NCBI
30.	Moon HJ, Kwak JY, Kim EK, Choi JR, Hong SW, Kim MJ and Son EJ: The role of BRAFV600E mutation and ultrasonography for the surgical management of a thyroid nodule suspicious for papillary thyroid carcinoma on cytology. Ann Surg Oncol. 16:3125–3131. 2009. View Article : Google Scholar : PubMed/NCBI
31.	Marchetti I, Lessi F, Mazzanti CM, Bertacca G, Elisei R, Coscio G, Pinchera A and Bevilacqua G: A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in pre-operative evaluation of fine-needle aspirates. Thyroid. 19:837–842. 2009. View Article : Google Scholar : PubMed/NCBI
32.	Bentz BG, Miller BT, Holden JA, Rowe LR and Bentz JS: B-RAF V600E mutational analysis of fine needle aspirates correlates with diagnosis of thyroid nodules. Otolaryngol Head Neck Surg. 140:709–714. 2009. View Article : Google Scholar : PubMed/NCBI
33.	Kim SK, Song KH, Lim SD, Lim YC, Yoo YB, Kim JS and Hwang TS: Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid. 19:137–141. 2009. View Article : Google Scholar : PubMed/NCBI
34.	Jo YS, Huang S, Kim YJ, Lee IS, Kim SS, Kim JR, Oh T, Moon Y, An S, Ro HK, Kim JM and Shong M: Diagnostic value of pyro-sequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. Clin Endocrinol (Oxf). 70:139–144. 2009. View Article : Google Scholar : PubMed/NCBI
35.	Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ and Qu JM: The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol. 17:3294–3300. 2010. View Article : Google Scholar : PubMed/NCBI
36.	Dujardin F, Pagès JC, Collin C, de Calan L, Lecomte P and Guyétant S: BRAF V600E mutation in papillary thyroid carcinoma: prevalence and detection in fine needle aspiration specimens. Ann Pathol. 30:252–262. 2010.(In French).
37.	Girlando S, Cuorvo LV, Bonzanini M, Morelli L, Amadori P, Dalla Palma P and Barbareschi M: High prevalence of B-RAF mutation in papillary carcinoma of the thyroid in north-east Italy. Int J Surg Pathol. 18:173–176. 2010. View Article : Google Scholar : PubMed/NCBI
38.	Musholt TJ, Fottner C, Weber MM, Eichhorn W, Pohlenz J, Musholt PB, Springer E and Schad A: Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg. 34:2595–2603. 2010. View Article : Google Scholar : PubMed/NCBI
39.	Kim SW, Lee JI, Kim JW, Ki CS, Oh YL, Choi YL, Shin JH, Kim HK, Jang HW and Chung JH: BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab. 95:3693–3700. 2010. View Article : Google Scholar : PubMed/NCBI
40.	Guo F, Hou P and Shi B: Detection of BRAF mutation on fine needle aspiration biopsy specimens: diagnostic and clinical implications for papillary thyroid cancer. Acta Cytol. 54:291–295. 2010. View Article : Google Scholar : PubMed/NCBI
41.	Kwak JY, Kim EK, Kim JK, Han JH, Hong SW, Park TS and Choi JR: Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAF(V600E) mutation in FNAB samples of thyroid nodules in BRAF(V600E) mutation-prevalent area. Head Neck. 32:490–498. 2010.PubMed/NCBI
42.	Ohori NP, Nikiforova MN, Schoedel KE, LeBeau SO, Hodak SP, Seethala RR, Carty SE, Ogilvie JB, Yip L and Nikiforov YE: Contribution of molecular testing to thyroid fine-needle aspiration cytology of ‘follicular lesion of undetermined significance/atypia of undetermined significance’. Cancer Cytopathol. 118:17–23. 2010.
43.	Moses W, Weng J, Sansano I, Peng M, Khanafshar E, Ljung BM, Duh QY, Clark OH and Kebebew E: Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg. 34:2589–2594. 2010. View Article : Google Scholar : PubMed/NCBI
44.	Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, Lim SD, Kim WS and Paik NS: Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab. 96:658–664. 2011. View Article : Google Scholar : PubMed/NCBI
45.	Yeo MK, Liang ZL, Oh T, Moon Y, An S, Kim MK, Kim KS, Shong M, Kim JM and Jo YS: Pyrosequencing cut-off value identifying BRAFV600E mutation in fine needle aspiration samples of thyroid nodules. Clin Endocrinol (Oxf). 75:555–560. 2011. View Article : Google Scholar : PubMed/NCBI
46.	Adeniran AJ, Theoharis C, Hui P, Prasad ML, Hammers L, Carling T, Udelsman R and Chhieng DC: Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study. Thyroid. 21:717–723. 2011. View Article : Google Scholar : PubMed/NCBI
47.	Pelizzo MR, Boschin IM, Barollo S, Pennelli G, Toniato A, Zambonin L, Vianello F, Piotto A, Ide EC, Pagetta C, Sorgato N, Torresan F, Girelli ME, Nacamulli D, Mantero F and Mian C: BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves pre-operative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. Clin Chem Lab Med. 49:325–329. 2011. View Article : Google Scholar